Guyasuta Investment Advisors Inc. Decreases Stock Position in Becton, Dickinson and Company $BDX

02 Jan 2026, 06:22 by Amy Steele · The Cerbat Gem

Guyasuta Investment Advisors Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 1.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 176,733 shares of the medical instruments supplier’s stock after selling 3,294 shares during the period. Becton, Dickinson and Company comprises approximately 1.9% of Guyasuta Investment Advisors Inc.’s holdings, making the stock its 13th biggest holding. Guyasuta Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $33,079,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the last quarter. RiverGlades Family Offices LLC acquired a new position in Becton, Dickinson and Company in the second quarter worth about $344,000. B. Riley Wealth Advisors Inc. bought a new stake in Becton, Dickinson and Company in the second quarter valued at about $983,000. Covea Finance raised its stake in Becton, Dickinson and Company by 10.7% during the third quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock valued at $14,758,000 after buying an additional 7,610 shares in the last quarter. Finally, Hutchinson Financial Advisors INC bought a new position in Becton, Dickinson and Company during the 2nd quarter worth approximately $1,024,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 0.8%

NYSE:BDX opened at $194.11 on Friday. The stock has a market cap of $55.30 billion, a price-to-earnings ratio of 33.30, a PEG ratio of 1.79 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The business has a fifty day moving average of $190.85 and a 200-day moving average of $186.79.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. This represents a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,052 shares of company stock worth $201,235 in the last quarter. Company insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada upped their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Jefferies Financial Group increased their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $205.64.

Get Our Latest Report on BDX

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.